Acta Biomaterialia, Journal Year: 2024, Volume and Issue: 192, P. 328 - 339
Published: Nov. 24, 2024
Language: Английский
Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)
Published: Jan. 13, 2025
This review highlights recent progress in exosome-based drug delivery for cancer therapy, covering exosome biogenesis, cargo selection mechanisms, and their application across multiple types. As small extracellular vesicles, exosomes exhibit high biocompatibility low immunogenicity, making them ideal vehicles capable of efficiently targeting cells, minimizing off-target damage side effects. aims to explore the potential with a focus on applications chemotherapy, gene immunomodulation. Additionally, challenges related production standardization are analyzed, highlighting importance addressing these issues clinical application. In conclusion, systems offer promising future therapies. Further research should aim enhance efficiency facilitate translation, paving way innovative treatment strategies.
Language: Английский
Citations
19
Advanced Science, Journal Year: 2024, Volume and Issue: 11(25)
Published: April 26, 2024
Cancer vaccines offer a promising avenue in cancer immunotherapy by inducing systemic, tumor-specific immune responses. Tumor extracellular vesicles (TEVs) are nanoparticles naturally laden with tumor antigens, making them appealing for vaccine development. However, their inherent malignant properties from the original cells limit direct therapeutic use. This study introduces novel approach to repurpose TEVs as potent personalized vaccines. The shows that inhibition of both YAP and autophagy not only diminishes malignancy-associated traits but also enhances immunogenic attributes enriching load antigens adjuvants. These revamped TEVs, termed attenuated yet immunogenically potentiated (AI-TEVs), showcase potential inhibiting growth, preventive measure possible treatment recurrent cancers. They prompt enduring memory. In addition, showing AI-TEVs can counteract growth approach, strategy is presented developing postoperative that's tailored individual patients.
Language: Английский
Citations
11
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 330 - 347
Published: Feb. 8, 2025
Language: Английский
Citations
1
Published: Jan. 1, 2025
Cancer nanovaccines represent a promising approach to cancer immunotherapy, offering advantages such as safety, efficacy, and personalization. However, challenges complex compositions, limited structural control, significant side effects impede their clinical application. In this study, we developed strategy for preparing through the co-assembly of well-defined single-component organic small molecules with antigens. By carefully adjusting length alkyl chains within molecules, achieved precise control over assembly behavior final optimized antigen-loading efficiency. After elucidating relationship between molecular structure resulting nanovaccine assemblies, identified molecule TCSVP, which serves both potent adjuvant an effective antigen carrier. Interestingly, TCSVP efficiently activates STING pathway in dendritic cells. Furthermore, three preventive tumor models, complete resistance rate ≥ 50% against inoculation established robust immune memory lasting up 135 days. Additionally, compared commercially available Freund's adjuvant, demonstrated superior activation while exhibiting negligible immune-related inflammatory effects, indicating favorable safety efficacy profile. This work not only highlights potential development advanced but also provides valuable insights design molecule-based self-adjuvanting nanovaccines.
Language: Английский
Citations
0
Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 159979 - 159979
Published: Jan. 1, 2025
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113614 - 113614
Published: March 1, 2025
Language: Английский
Citations
0
Small Methods, Journal Year: 2025, Volume and Issue: unknown
Published: April 8, 2025
Abstract Exosomes, small extracellular vesicles with lipid bilayer membranes, play a crucial role in cellular communication and can transfer diverse biological cargo, including proteins, lipids, nucleic acids, from donor to recipient cells. Exosomes possess immunological properties, such as antigen delivery immune activation, along excellent drug capabilities, making them promising candidates for vaccine development. For different diseases, exosome‐based vaccines be designed therapeutic or prophylactic by leveraging immunity humoral immunity. With the emergence of precision medicine, personalized demonstrate exceptional potential. This review systematically introduces sources, biogenesis mechanisms, components exosomes describes their regulatory roles system. Subsequently, preparation, administration, therapy are discussed. Finally, applications clinical trials fields anti‐infection anti‐tumor therapies particularly highlighted, an analysis potential challenges future
Language: Английский
Citations
0
Small, Journal Year: 2025, Volume and Issue: unknown
Published: April 21, 2025
Abstract Cancer vaccines hold promise for tumor immunotherapy, with their success hinging on effective systems to boost anti‐tumor immunity. Biological membranes are not only a delivery vehicle but also source of antigens and adjuvants, garnering growing interest in vaccine research. This review starts an introduction the composition mechanisms cancer describes sources, advantages/disadvantages, engineering strategies, applications these membrane‐based platforms development. offers critical analysis discusses further direction platform view clinical translation immunotherapy.
Language: Английский
Citations
0
Deleted Journal, Journal Year: 2025, Volume and Issue: unknown
Published: May 4, 2025
Abstract Extracellular vesicles (EVs) are lipid bilayer structures secreted by cells that act as intercellular messengers. Tissue‐derived EVs (TEVs), harvested from the tissue interstitium, directly reflect actual physiological or pathological state of microenvironment. However, difficulty in acquisition severely limits development TEVs. In contrast, organoids 3D cell clusters cultured stem cells, which have spatial and functions highly similar to source tissues. Although organoid‐derived (OEVs), isolated culture supernatants, can complex cellular interactions, they cannot microenvironment like Building on foundation TEVs OEVs, we introduce innovative concept organoid‐tissue (OTEVs), where residing organoid interstitium. Acting a communication bridge between OEVs TEVs, OTEVs accurately represent true They overcome challenges associated with limited availability inability We believe will synergize enhance understanding pathogenesis diseases, well improve their diagnosis treatment.
Language: Английский
Citations
0
Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(8)
Published: Aug. 1, 2024
Pharmacokinetics (PK) and pharmacodynamics (PD) are central concepts to guide the dosage administration of drug therapies essential consider for both healthcare professionals researchers in therapeutic planning discovery. PK/PD properties a significantly influence variability response treatment, including failure or excessive medication-related harm. Furthermore, suboptimal PK constitute significant barrier further development some candidate treatments This article describes how extracellular vesicles (EVs) affect different aspects PD medications their potential modulate address problematic profiles drugs. We reviewed EVs' intrinsic effects on cell behaviours medication responses. also described surface cargo modifications can enhance EV functionalities enable them as adjuvants optimise profile conventional medications. we demonstrated that various bioengineering strategies be used modify EVs, hence enhancing
Language: Английский
Citations
2